PMID- 35360715
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220402
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - The Effect of Sacubitril/Valsartan Treatment on Cardiac and Renal Functions of a 
      Patient With Cardiorenal Syndrome Type 4 and Stage 5 CKD After More Than Three 
      Years of Follow-Up.
PG  - 817833
LID - 10.3389/fmed.2022.817833 [doi]
LID - 817833
AB  - It is difficult to treat cardiorenal syndrome (CRS) in clinical practice, which 
      is the common reason for the death of patients. This report aimed to describe the 
      effects of sacubitril/valsartan treatment on cardiac and renal functions of a 
      patient with cardiorenal syndrome type 4 (CRS4) after more than 3 years of 
      follow-up. A 77-year-old Chinese woman was admitted to our hospital because of 
      CRS4 and stage 5 chronic kidney disease (CKD), who had a history of long-term 
      proteinuria and renal failure. The patient's cardiothoracic ratio (CTR) measured 
      by chest X-ray was 0.6. Cardiac ultrasonography showed that the left ventricular 
      ejection fraction (LVEF) was 0.40. The patient had been treated for heart failure 
      (HF) for 5 months, but there was no improvement in clinical manifestations, and 
      the renal function gradually deteriorated. In our hospital, she received 
      sacubitril/valsartan treatment for at least 40 months. The symptoms of HF 
      relieved, and the indices of cardiac function improved. In addition, the 
      patient's renal function was stable. During the treatment, the dosage of 
      sacubitril/valsartan needed to be adjusted to achieve the optimal therapeutic 
      effect. Follow-up results showed that she achieved cardiac function of New York 
      Heart Association (NYHA) class II with an ejection fraction of 0.60 and E/A > 1 
      indicated by echocardiogram, and did not develop hyperkalemia. In summary, the 
      improvement of cardiac and renal functions of the CRS4 patient was associated 
      with the long-term sacubitril/valsartan treatment.
CI  - Copyright (c) 2022 Cheng, Zhou, Yu, Chen, Zhang, Wang and Yu.
FAU - Cheng, Shuiqin
AU  - Cheng S
AD  - Department of Nephrology, National Clinical Research Center of Kidney Disease, 
      Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
FAU - Zhou, Tingting
AU  - Zhou T
AD  - Department of Nephrology, National Clinical Research Center of Kidney Disease, 
      Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
FAU - Yu, Le
AU  - Yu L
AD  - Department of Nephrology, National Clinical Research Center of Kidney Disease, 
      Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
FAU - Chen, Yunmin
AU  - Chen Y
AD  - Department of Nephrology, National Clinical Research Center of Kidney Disease, 
      Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
FAU - Zhang, Zhihong
AU  - Zhang Z
AD  - Department of Nephrology, National Clinical Research Center of Kidney Disease, 
      Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
FAU - Wang, Jinquan
AU  - Wang J
AD  - Department of Nephrology, National Clinical Research Center of Kidney Disease, 
      Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
FAU - Yu, Yusheng
AU  - Yu Y
AD  - Department of Nephrology, National Clinical Research Center of Kidney Disease, 
      Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20220311
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8962615
OTO - NOTNLM
OT  - cardiac function
OT  - cardiorenal syndrome type 4
OT  - long-term follow-up
OT  - renal function
OT  - sacubitril/valsartan
OT  - stage 5 CKD
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/02 06:00
MHDA- 2022/04/02 06:01
PMCR- 2022/03/11
CRDT- 2022/04/01 05:26
PHST- 2021/11/18 00:00 [received]
PHST- 2022/02/11 00:00 [accepted]
PHST- 2022/04/01 05:26 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/02 06:01 [medline]
PHST- 2022/03/11 00:00 [pmc-release]
AID - 10.3389/fmed.2022.817833 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Mar 11;9:817833. doi: 10.3389/fmed.2022.817833. 
      eCollection 2022.